RespiratoryInfectious Disease
Active Tuberculosis — Diagnosis & Management
NICE NG33 — clinical recognition, diagnostics (sputum, NAAT, culture), standard 6-month RIPE regimen, monitoring, public-health notification.
Source: NICE NG33 (2016, updates 2019); WHO 2022
Step 1 of ~5
info
Recognise & Investigate
Suspect: persistent cough >3 weeks, fevers, night sweats, weight loss, haemoptysis; risk groups (homelessness, IVDU, HIV, immunosuppressed, prison, recent contact with active TB, born in high-prevalence country). ABCDE; isolate (single side room with negative pressure if available); FFP3 mask for staff; bloods (FBC, U&E, LFTs, HIV test, glucose); CXR (cavitating upper-lobe consolidation classical); sputum × 3 for AFB smear, NAAT (Xpert MTB/RIF — rifampicin resistance), and culture (gold standard but slow).
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Ethambutol · Antitubercular — First-Line TB (RIPE Regimen, 'E')
- Pyrazinamide · Antitubercular — First-Line TB (RIPE Regimen, 'P')
- Insulin (IV Infusion — ICU Glucose Control) · Insulin — ICU Glucose Management
- Sodium Chloride 3% (Hypertonic Saline) · Hypertonic Electrolyte Solution — ICP/Hyponatraemia Management
- Hydrocortisone (Oral Replacement) · Glucocorticoid Replacement
- Alfacalcidol (1-alpha-Hydroxycholecalciferol) · Active Vitamin D Analogue
Pathways
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024
Decision support only. Always apply local guidelines and clinical judgement.